Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees

Executive Summary

Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich

You may also be interested in...



U.S. FDA Pilot Program Will Speed U.S. Entry Of Drugs With Secure Supply Chains

FDA is developing an implementation plan for pilot testing a program to speed entry into the U.S. of drugs that flow through a strong supply chain

FDA Pilot Program Will Speed U.S. Entry Of Drugs With Secure Supply Chains

FDA is developing an implementation plan for pilot testing a program to speed entry into the U.S. of drugs that flow through a strong supply chain.

FDA Pilot Program Will Speed U.S. Entry Of Drugs With Secure Supply Chains

FDA is developing an implementation plan for pilot testing a program to speed entry into the U.S. of drugs that flow through a strong supply chain.

Related Content

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel